Positive macro trends, technical indicators, and skeptical sentiment point to a continued stock market uptrend. Click here to ...

It seems to be another quiet trading day on Wall Street, as investors await next major catalyst to dictate the near-term direction of the stock market. Under the calm surface, however, there is ...

This was the stock's fourth consecutive day of gains.

Key Points Energy, healthcare, and chip stocks have driven the market higher today. Tesla has stopped falling and has ...

The Australian sharemarket’s latest high reflects two big shifts in global equites sparked by Donald Trump. Here’s how to ...

What a brutal six months it’s been for UnitedHealth. The stock has dropped 46.3% and now trades at $303.30, rattling many ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's in a second fertility clinic mix-up, heightening concerns about an industry that did ...

The Board of Directors of Aayush Wellness Limited, an integrated healthcare company dedicated to holistic wellness and ...

ZYNYZ, a PD-1 inhibitor developed by MacroGenics and licensed to Incyte (NASDAQ: INCY ), is indicated for certain types of cancer, including squamous cell carcinoma of the anal canal and Merkel cell ...